Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer. BMC Cancer. 2024;24(1):1377. Published 2024 Nov 11. doi:10.1186/s12885-024-13087-8 Fu YP, Lin H, Ou YC, Wu CH, Fu HC.